S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal

Organogenesis (ORGO) Stock Price, News & Analysis

$2.88
-0.12 (-4.00%)
(As of 04/12/2024 ET)
Today's Range
$2.79
$3.02
50-Day Range
$2.61
$3.84
52-Week Range
$1.79
$4.70
Volume
404,580 shs
Average Volume
927,278 shs
Market Capitalization
$380.04 million
P/E Ratio
72.02
Dividend Yield
N/A
Price Target
$4.83

Organogenesis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
67.8% Upside
$4.83 Price Target
Short Interest
Healthy
9.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

114th out of 923 stocks

Pharmaceutical Preparations Industry

42nd out of 428 stocks

ORGO stock logo

About Organogenesis Stock (NASDAQ:ORGO)

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO Stock Price History

ORGO Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Organogenesis Holdings Inc. Cl A
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Recap: Organogenesis Hldgs Q4 Earnings
A Preview Of Organogenesis Hldgs's Earnings
Organogenesis Holdings Inc - Ordinary Shares - Class A
3 Biotech Stocks Flowing With Investment Potential
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/13/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
862
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+67.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$4.95 million
Pretax Margin
2.40%

Debt

Sales & Book Value

Annual Sales
$433.14 million
Cash Flow
$0.21 per share
Book Value
$2.11 per share

Miscellaneous

Free Float
87,096,000
Market Cap
$380.04 million
Optionable
Optionable
Beta
1.57
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

ORGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ORGO shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price target for 2024?

3 analysts have issued twelve-month target prices for Organogenesis' shares. Their ORGO share price targets range from $3.50 to $6.00. On average, they predict the company's stock price to reach $4.83 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2024?

Organogenesis' stock was trading at $4.09 at the beginning of 2024. Since then, ORGO shares have decreased by 29.6% and is now trading at $2.88.
View the best growth stocks for 2024 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ORGO earnings forecast
.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) released its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The business earned $113.75 million during the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a net margin of 1.14% and a trailing twelve-month return on equity of 1.81%. During the same quarter last year, the business earned $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $445.0 million-$470.0 million, compared to the consensus revenue estimate of $456.0 million.

What other stocks do shareholders of Organogenesis own?
Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.38%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz and Michael W Katz.
View institutional ownership trends
.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGO) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners